ID   Hep-KANO clone 2
AC   CVCL_Y144
SY   Hep-KANO CL-2; Hep-KANO CL2
DR   CGH-DB; 9077-4
DR   Wikidata; Q54882795
RX   PubMed=7829395;
RX   PubMed=12029633;
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=7829395).
CC   Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_Y143 ! Hep-KANO clone 1
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 21-03-23; Version: 6
//
RX   PubMed=7829395; DOI=10.1111/j.1349-7006.1994.tb02914.x;
RA   Baba M., Hasegawa H., Nakayabu M., Tamaki S., Watanabe S., Shima T.,
RA   Suzuki S., Kusano I., Kamada N.;
RT   "Characteristics of human hepatocellular carcinoma cell lines
RT   (Hep-KANO) derived from a non-hepatitic, non-cirrhotic hepatitis B
RT   virus carrier.";
RL   Jpn. J. Cancer Res. 85:1105-1111(1994).
//
RX   PubMed=12029633; DOI=10.1053/jhep.2002.33683;
RA   Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M.,
RA   Inazawa J.;
RT   "TFDP1, CUL4A, and CDC16 identified as targets for amplification at
RT   13q34 in hepatocellular carcinomas.";
RL   Hepatology 35:1476-1484(2002).
//